FEMSelect Raises US$9M in Series B Financing


FemSelect, a Tel Aviv, Israel-based developer of an leading edge solution to pelvic flooring ligament fixation, raised US$9M in Sequence B investment.

The spherical used to be led by means of New Age Ventures, and TriVentures, with participation from Robin Hood Ventures, Mid Atlantic Bio Angels, MEDA Angels, Keiretsu Discussion board Mid-Atlantic, RAD BioMed, Keiretsu Capital and Transpacific Mission Companions. Following its funding, New Age Ventures will sign up for FEMSelect’s Board of Administrators.

The corporate intends to make use of the price range to make stronger the expansion and marketplace penetration of EnPlace®, basically in the USA.

Led Co-CEOs Debbie Garner and Renee Selman, FEMSelect develops EnPlace®, a minimally invasive, meshless solution to pelvic flooring ligament fixation. The device is cleared by means of the FDA for pelvic flooring ligament fixation for the control of symptomatic uterine prolapse, a complication within the lives of just about 50% of girls over the age of fifty. The era allows a minimally invasive manner in underneath half-hour and medical research have proven girls can go back to standard actions inside only some days. 

FEMSelect partnered with girls’s healthcare corporate LiNA Scientific USA and has been teaching physicians at the era during the last yr. Previous this yr, EnPlace® bought a process code from the Facilities for Medicare and Medicaid Services and products (CMS) enabling healthcare amenities to obtain compensation for the process.

It is lately to be had in additional than 25 states throughout the USA. 



Table of Contents


Debbie has twenty years of revel in in commercialization management roles. She has introduced and constructed the marketplace for leading edge girls’s well being care merchandise with Eli Lilly and Co. and iMDsoft in a large number of global markets. Debbie holds an MBA from the Wharton Faculty of Trade of the College of Pennsylvania and a BA from Harvard School.

Renee Selman 2

Leave a Comment